具体为:1TKI药物选择:考虑患儿个体化差异,从疾病诊断风险、经济承受能力、ABL1激酶区突变等多个因素来选择TKI药物。2诱导化疗方案:淋系急变(Chronic myeloid leukemia lymphoid blast phase,CML-LBP)者主要为地塞米松、长春碱类、蒽环类、门冬酰胺酶、环磷酰胺等。髓系急变(Chronic myeloid leukemia myeloid blast phase,CML-MBP)者主要为阿糖胞苷、高三尖杉酯碱、蒽环类或亚砷酸等。混合表型白血病急变(Chronic myeloid leukemia mixed phenotype acute leukemia, CML-MPAL)者主要参考CML-LBP的方案。3HSCT方案:依据患儿与供者骨髓人类白细胞抗原(HLA)配型结果等进行半相合HSCT或全相合HSCT。. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.